Sareum: Focused on cancer and autoimmune disease




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Sareum: Focused on cancer and autoimmune disease
Released on: December 19, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Sareum discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases.
  • Summary
  • Participants
  • Company
Sareum discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases. Our drug development programmes aim to improve outcomes for patients with serious medical conditions and where current therapies are inadequate.
Dr Tim Mitchell, aged 55, has a wide breadth of management, business and research expertise gained over 25 years in the biotech, large pharmaceutical and research service companies. He is the inventor of ObleanĀ® (cetilistat) which Takeda have obtained sales approval in the Japanese market for the treatment of obesity with complications. Prior to co-founding Sareum he was Director of Structure-Based Discovery at Millennium Pharmaceuticals, Director of Computational Chemistry at Cambridge Discovery Chemistry, and Team Leader at SmithKline Beecham Pharmaceuticals. Tim has a PhD in Computational Chemistry and a BSc in Chemistry.
Sareum discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases. Our drug development programmes aim to improve outcomes for patients with serious medical conditions and where current therapies are inadequate. Chk1 was licensed to ProNAi Therapeutics, inc. (NASDAQ:DNAI) in September 2016. We are currently pursuing our other drug discovery and development programmes in collaboration with Hebei Medical University Biomedical Engineering Center (Aurora+FLT3) and SRI International (TYK2 Autoimmune) whilst TYK2 Cancer is funded internally.